Smoking Cessation - Data, Analysis & Forecasts to 2023
GMR Data’s new pharmaceutical report outlines the factors affecting the global smoking cessation market across the forecast period 2013-2023. The report outlines key drivers and restraints of the market in all key global geographies.
Drivers include:
This report also breaks down the market in terms of current smoking cessation drugs and products that occupy the market at present; examining the key prescription and OTC drugs that drive the market. In addition to this crucial information this report offers analysis and opinion on current R&D in the smoking cessation sector alongside in depth analysis of the emerging, global e-cigarette market.
This report also includes 3 original, exclusive, interview transcripts with key global pharmaceutical companies:
Drivers include:
- Increased health care / health education in many geographies
- Adoption of smoking cessation products onto health insurance policies
- Increasing number of smoking cessation products emerging onto the market
- Emergence of e-cigarettes onto the global market
- Over 1bn smokers world wide
This report also breaks down the market in terms of current smoking cessation drugs and products that occupy the market at present; examining the key prescription and OTC drugs that drive the market. In addition to this crucial information this report offers analysis and opinion on current R&D in the smoking cessation sector alongside in depth analysis of the emerging, global e-cigarette market.
This report also includes 3 original, exclusive, interview transcripts with key global pharmaceutical companies:
- Pfizer
- Elder Pharmaceuticals
- GlaxoSmithKline
1 EXECUTIVE SUMMARY
1.1. Smoking Cessation Market Review
1.2. Chapter Breakdown
1.3. Research and Analysis Methods
2 INTRODUCTION TO SMOKING CESSATION
2.1. Smoking Cessation Treatment Overview
2.1.1. Nicotine Replacement Therapy (NRT)
2.1.2. Non-NRT Therapy
2.2. Global Tobacco Consumption Prevalence, Trends & Impact
2.2.1. Prevalence of Death Caused due to Tobacco
2.2.2. Second-Hand Smoking
2.2.3. Increased Awareness of Health Implications in Relation to Smoking
2.2.4. Enforcement of Bans on Tobacco Product Advertising & Promotions
2.2.5. Increased Taxation
3 SMOKING CESSATION MARKET FORECASTS
3.1. Global Smoking Cessation Market
3.1.1. Global Smoking Cessation Market
3.1.2. Global Prescription Drugs Smoking Cessation Market
4 KEY GLOBAL SMOKING CESSATION MARKETS 2013-2023
4.1. The US Smoking Cessation Market - Set to Occupy 45-50% of the Global Market Across 2013-2023
4.2. The UK Smoking Cessation Market - How Will This Mature Market Grow Through 2013-2023?
4.3. The France Smoking Cessation Market - How Much of the Global Smoking Cessation Market Will France Occupy to 2023?
4.4. The German Smoking Cessation Market - Will Reduced German Tobacco Consumption Drive the Smoking Cessation Market?
4.5. The Spanish Smoking Cessation Market - The Strictest Anti-Smoking Laws in the EU, How Will This Affect The Spanish Smoking Cessation Market?
4.6. The Italian Smoking Cessation Market - How Will Strong E-cigarette Sales Affect Other NRT Products in the Italian Smoking Cessation Market?
4.7. The Japanese Smoking Cessation Market - Why Does GMR Data Forecast a Low Growth Rate in the Japanese Smoking Cessation Market?
4.8. The Rest of World Smoking Cessation Market - How Will Emerging Markets, Such as India & China, Affect theGlobal Smoking Cessation Market Across 2013-2023?
5 NICOTINE REPLACEMENT THERAPIES (NRT) MARKET
5.1. NicoDerm CQ
5.2. Nicotrol
5.3. Habitrol (Nicotinell)
5.4. Nicorette
6 PRESCRIPTION DRUGS SMOKING CESSATION MARKET
6.1. Chantix (by Pfizer): Varenicline
6.2. Zyban / Wellbutrin (by GSK): bupropion
7 LEADING COMPANIES IN THE GLOBAL SMOKING CESSATION MARKET
7.1. Pfizer
7.2. GlaxoSmithKline (GSK)
7.3. Novartis
7.4. Johnson & Johnson (J&J)
7.5. Perrigo
7.6. Sophomore and Extab
7.7. 22nd Century Group, Inc.
8 SWOT ANALYSIS OF THE SMOKING CESSATION MARKET
8.1. Strengths
8.1.1. FDA Relaxation in the NRT Market
8.1.2. Increased Insurance Cover for Smoking Cessation Products
8.1.3. Strong Mature Markets
8.2. Weaknesses
8.2.1. Weak R&D pipeline for the smoking cessation market
8.2.2. Side Effects to Current Drugs/Therapies on the Market
8.3. Opportunities
8.3.1. E-cigarettes
8.3.1.1. E-cigarettes Legal Status
8.3.1.2. E-cigarettes background
8.3.1.3. Geographic Breakdown & Market Share for E-cigarettes
8.3.1.4 Market Forecast
8.3.1.5 E-cigarette Industry Regulation
8.3.2. Future Research on Drugs/Therapies Currently on the Market
8.3.3. Strong Emerging Markets
8.4. Threats
8.4.1 Pool of Smokers Greatly Reduced in Some Key Markets
8.4.2 New Drug / Product threat
9 EXPERT INTERVIEWS
9.1. Pfizer
9.2. Elder Pharmaceuticals
9.3. GlaxoSmithKline
1.1. Smoking Cessation Market Review
1.2. Chapter Breakdown
1.3. Research and Analysis Methods
2 INTRODUCTION TO SMOKING CESSATION
2.1. Smoking Cessation Treatment Overview
2.1.1. Nicotine Replacement Therapy (NRT)
2.1.2. Non-NRT Therapy
2.2. Global Tobacco Consumption Prevalence, Trends & Impact
2.2.1. Prevalence of Death Caused due to Tobacco
2.2.2. Second-Hand Smoking
2.2.3. Increased Awareness of Health Implications in Relation to Smoking
2.2.4. Enforcement of Bans on Tobacco Product Advertising & Promotions
2.2.5. Increased Taxation
3 SMOKING CESSATION MARKET FORECASTS
3.1. Global Smoking Cessation Market
3.1.1. Global Smoking Cessation Market
3.1.2. Global Prescription Drugs Smoking Cessation Market
4 KEY GLOBAL SMOKING CESSATION MARKETS 2013-2023
4.1. The US Smoking Cessation Market - Set to Occupy 45-50% of the Global Market Across 2013-2023
4.2. The UK Smoking Cessation Market - How Will This Mature Market Grow Through 2013-2023?
4.3. The France Smoking Cessation Market - How Much of the Global Smoking Cessation Market Will France Occupy to 2023?
4.4. The German Smoking Cessation Market - Will Reduced German Tobacco Consumption Drive the Smoking Cessation Market?
4.5. The Spanish Smoking Cessation Market - The Strictest Anti-Smoking Laws in the EU, How Will This Affect The Spanish Smoking Cessation Market?
4.6. The Italian Smoking Cessation Market - How Will Strong E-cigarette Sales Affect Other NRT Products in the Italian Smoking Cessation Market?
4.7. The Japanese Smoking Cessation Market - Why Does GMR Data Forecast a Low Growth Rate in the Japanese Smoking Cessation Market?
4.8. The Rest of World Smoking Cessation Market - How Will Emerging Markets, Such as India & China, Affect theGlobal Smoking Cessation Market Across 2013-2023?
5 NICOTINE REPLACEMENT THERAPIES (NRT) MARKET
5.1. NicoDerm CQ
5.2. Nicotrol
5.3. Habitrol (Nicotinell)
5.4. Nicorette
6 PRESCRIPTION DRUGS SMOKING CESSATION MARKET
6.1. Chantix (by Pfizer): Varenicline
6.2. Zyban / Wellbutrin (by GSK): bupropion
7 LEADING COMPANIES IN THE GLOBAL SMOKING CESSATION MARKET
7.1. Pfizer
7.2. GlaxoSmithKline (GSK)
7.3. Novartis
7.4. Johnson & Johnson (J&J)
7.5. Perrigo
7.6. Sophomore and Extab
7.7. 22nd Century Group, Inc.
8 SWOT ANALYSIS OF THE SMOKING CESSATION MARKET
8.1. Strengths
8.1.1. FDA Relaxation in the NRT Market
8.1.2. Increased Insurance Cover for Smoking Cessation Products
8.1.3. Strong Mature Markets
8.2. Weaknesses
8.2.1. Weak R&D pipeline for the smoking cessation market
8.2.2. Side Effects to Current Drugs/Therapies on the Market
8.3. Opportunities
8.3.1. E-cigarettes
8.3.1.1. E-cigarettes Legal Status
8.3.1.2. E-cigarettes background
8.3.1.3. Geographic Breakdown & Market Share for E-cigarettes
8.3.1.4 Market Forecast
8.3.1.5 E-cigarette Industry Regulation
8.3.2. Future Research on Drugs/Therapies Currently on the Market
8.3.3. Strong Emerging Markets
8.4. Threats
8.4.1 Pool of Smokers Greatly Reduced in Some Key Markets
8.4.2 New Drug / Product threat
9 EXPERT INTERVIEWS
9.1. Pfizer
9.2. Elder Pharmaceuticals
9.3. GlaxoSmithKline
LIST OF TABLES
Table 2.2.1 Prevalence of tobacco use among adults in selected countries—males and females, 2010
Table 2.2.2: Non-Smoking Adults Working Indoors Who Are Exposed to Second-hand Tobacco Smoke, 2008 – 2010
Table 2.2.3: BRIC Population, GDP per Capita 2000 & 2010 ($/per annum)
Table 2.2.3.1: Smokers Reporting Six Months Continued Cessation with Different Interventions
Table 2.2.3.2: Adult Smokers Who Do Not Believe, or Do Not Know That Smoking Causes Specific Diseases, by Country
Table 3.1 Global Smoking Cessation Market Forecast 2013-2023 ($m)
Table 3.1.a: Key NRT Products Revenue Forecast 2013, 2018 & 2023 ($/m)
Table 3.1.b Global Smoking Cessation Market - Breakdown ($m)
Table 3.1.1 Global NRT Smoking Cessation Market Forecast 2013-2023 ($/m)
Table 3.1.2 Global Prescription Drugs Smoking Cessation Market Forecast 2013-2023 ($/m)
Table 4.a The Global Smoking Cessation Market Forecast 2012 -2023, by Country ($/m per annum)
Table 4.b Key Countries CAGR 2013-2023 (%)
Table 4.c Estimated Smoking Cessation Market Share for Selected Countries 2013, 2018 and 2023 (%)
Table 4.1 the US Smoking Cessation Market Forecast 2011-2023 ($/m)
Table 4.2 the UK Smoking Cessation Market Forecast 2012-2023 ($/m)
Table 4.2.1 EU5 Total Population & Population of Smokers 2012
Table 4.3 the France Smoking Cessation Market Forecast 2011-2023 ($ Million)
Table 4.4 the German Smoking Cessation Market Forecast 2011-2023 ($/m)
Table 4.4.1 Amount of Tobacco Sold in Germany 1995-2010 (Tonnes)
Table 4.5 the Spanish Smoking Cessation Market Forecast 2011-2023 ($ Million)
Table 4.5.1 The number of smokers in Spain (Million)
Table 4.6 The Italian Smoking Cessation Market Forecast 2011-2023 ($/m)
Table 4.7 the Japanese Smoking Cessation Market Forecast 2011-2023 ($/m)
Table 4.8 The Rest of the World Smoking Cessation Market Forecast 2011-2023 ($ Million)
Table 4.8.1 Estimated Smoking Cessation Market Share for Selected Countries 2013, 2018 and 2023 (%)
Table 4.8.2 BRIC Population, GDP 2000 & 2010, CAGR & GDP per Capita 2000 & 2010 ($/per annum)
Table 5.1 Market Forecast for Nicoderm CQ 2013-2023
Table 5.2 Global Nicotrol Market 2010-2012 ($m)
Table 5.2.1 Global Nicotrol Market Forecast 2013-2023 ($/m)
Table 5.3 Market Forecast for Habitrol/Nicotinell 2013-2023
Table 5.4 Market Forecast for Nicorette 2013-2023
Table 6 Tobacco Cessation Medications and Associated Side Effects
Table 6.1 Global Chantix/ Champix Market 2008 – 2012
Table 6.1.a Market Forecast for Chantix / Champix 2013-2023
Table 6.2 Market Forecast for Zyban 2013-2023
Table 7.1 Pfizer Smoking Cessation Pipeline
Table 7.2 Global Chantix / Champix Market 2008-2012
Table 7.3 Market Forecast for Chantix / Champix 2013-2023
Table 7.4 Market Forecast for Zyban 2013-2023
Table 8 SWOT Analysis
Table 8.1.3 US, UK, France & Japanese Smoking Cessation Markets 2012-2016 ($/ per annum)
Table 8.2.1 NRT Products Pipeline
Table 8.2.1.a Smoking Cessation Drugs /Products Pipeline
Table 8.2.2 Side Effects of major smoking cessation products
Table 8.3.1.2 Major E-cigarette Brands
Table 8.3.1.4 Market Forecast for E-Cigarettes 2013-2023
Table 8.3.1.4.a Costs per pack of cigarettes in Key countries
Table 8.3.3ROW Smoking Cessation Market Share 2013
Table 8.3.3.a Chinese & Indian Populations, Number of Smokers, GDP in 2000 & 2010 ($)
Table 2.2.1 Prevalence of tobacco use among adults in selected countries—males and females, 2010
Table 2.2.2: Non-Smoking Adults Working Indoors Who Are Exposed to Second-hand Tobacco Smoke, 2008 – 2010
Table 2.2.3: BRIC Population, GDP per Capita 2000 & 2010 ($/per annum)
Table 2.2.3.1: Smokers Reporting Six Months Continued Cessation with Different Interventions
Table 2.2.3.2: Adult Smokers Who Do Not Believe, or Do Not Know That Smoking Causes Specific Diseases, by Country
Table 3.1 Global Smoking Cessation Market Forecast 2013-2023 ($m)
Table 3.1.a: Key NRT Products Revenue Forecast 2013, 2018 & 2023 ($/m)
Table 3.1.b Global Smoking Cessation Market - Breakdown ($m)
Table 3.1.1 Global NRT Smoking Cessation Market Forecast 2013-2023 ($/m)
Table 3.1.2 Global Prescription Drugs Smoking Cessation Market Forecast 2013-2023 ($/m)
Table 4.a The Global Smoking Cessation Market Forecast 2012 -2023, by Country ($/m per annum)
Table 4.b Key Countries CAGR 2013-2023 (%)
Table 4.c Estimated Smoking Cessation Market Share for Selected Countries 2013, 2018 and 2023 (%)
Table 4.1 the US Smoking Cessation Market Forecast 2011-2023 ($/m)
Table 4.2 the UK Smoking Cessation Market Forecast 2012-2023 ($/m)
Table 4.2.1 EU5 Total Population & Population of Smokers 2012
Table 4.3 the France Smoking Cessation Market Forecast 2011-2023 ($ Million)
Table 4.4 the German Smoking Cessation Market Forecast 2011-2023 ($/m)
Table 4.4.1 Amount of Tobacco Sold in Germany 1995-2010 (Tonnes)
Table 4.5 the Spanish Smoking Cessation Market Forecast 2011-2023 ($ Million)
Table 4.5.1 The number of smokers in Spain (Million)
Table 4.6 The Italian Smoking Cessation Market Forecast 2011-2023 ($/m)
Table 4.7 the Japanese Smoking Cessation Market Forecast 2011-2023 ($/m)
Table 4.8 The Rest of the World Smoking Cessation Market Forecast 2011-2023 ($ Million)
Table 4.8.1 Estimated Smoking Cessation Market Share for Selected Countries 2013, 2018 and 2023 (%)
Table 4.8.2 BRIC Population, GDP 2000 & 2010, CAGR & GDP per Capita 2000 & 2010 ($/per annum)
Table 5.1 Market Forecast for Nicoderm CQ 2013-2023
Table 5.2 Global Nicotrol Market 2010-2012 ($m)
Table 5.2.1 Global Nicotrol Market Forecast 2013-2023 ($/m)
Table 5.3 Market Forecast for Habitrol/Nicotinell 2013-2023
Table 5.4 Market Forecast for Nicorette 2013-2023
Table 6 Tobacco Cessation Medications and Associated Side Effects
Table 6.1 Global Chantix/ Champix Market 2008 – 2012
Table 6.1.a Market Forecast for Chantix / Champix 2013-2023
Table 6.2 Market Forecast for Zyban 2013-2023
Table 7.1 Pfizer Smoking Cessation Pipeline
Table 7.2 Global Chantix / Champix Market 2008-2012
Table 7.3 Market Forecast for Chantix / Champix 2013-2023
Table 7.4 Market Forecast for Zyban 2013-2023
Table 8 SWOT Analysis
Table 8.1.3 US, UK, France & Japanese Smoking Cessation Markets 2012-2016 ($/ per annum)
Table 8.2.1 NRT Products Pipeline
Table 8.2.1.a Smoking Cessation Drugs /Products Pipeline
Table 8.2.2 Side Effects of major smoking cessation products
Table 8.3.1.2 Major E-cigarette Brands
Table 8.3.1.4 Market Forecast for E-Cigarettes 2013-2023
Table 8.3.1.4.a Costs per pack of cigarettes in Key countries
Table 8.3.3ROW Smoking Cessation Market Share 2013
Table 8.3.3.a Chinese & Indian Populations, Number of Smokers, GDP in 2000 & 2010 ($)
LIST OF FIGURES
Figure 2.2.1: Prevalence of tobacco use among adults in selected countries—males and females, 2010
Figure 2.2.4.1 Global Market Size as per Skin Cancer Type – Incidences
Figure 2.2.2 Non-Smoking Adults Working Indoors Who Are Exposed to Second-hand Tobacco Smoke, 2008 – 2010
Figure 2.2.3 Adult Smokers Who Do Not Believe, or Do Not Know That Smoking Causes Specific Diseases, by Country
Chart 2.2.5: Average Retail Price and Taxation (Excise and Total) of Most Sold Brands of Cigarettes, 2010
Figure 3.1 Global Smoking Cessation Market Forecasts 2013 to 2023
Figure 3.1.1 Global NRT Smoking Cessation Market Forecast 2013-2023
Figure 3.1.1.a Global NRT Smoking Cessation Market Share by Product Type
Figure 3.1.2 Global Prescription Drugs Smoking Cessation Market Forecast 2013-2023
Figure 4.a Global Market Share for Selected Countries 2013
Figure 4.b Global Market Share for Selected Countries 2018
Figure 4.c Global Market Share for Selected Countries 2023
Figure4.1. The US Smoking Cessation Market Forecast 2012-2023 ($/m)
Figure 4.2 Retail Sales of NRT Products in the UK 2012
Figure 4.2.a. The UK Smoking Cessation Market Forecast 2012-2023 ($ Million)
Figure 4.3. The France Smoking Cessation Market Forecast 2012-2023 ($ Million)
Figure 4.4 The German Smoking Cessation Market Forecast 2012-2023 ($ Million)
Figure 4.5. The Spanish Smoking Cessation Market Forecast 2012-2023 ($ Million)
Figure 4.6 The Italian Smoking Cessation Market Forecast 2012-2023 ($/m)
Figure 4.7 The Japanese Smoking Cessation Market Forecast 2012-2023 ($ Million)
Figure 4.8 The ROW Smoking Cessation Market Forecast 2012-2023 ($ Million)
Figure 5.1 Market Forecast for Nicoderm CQ 2013-2023
Figure 5.1.a Geographic Breakdown for Nicoderm CQ 2012 & 2023
Figure 5.2 Global Revenue for Nicotrol 2010-2012
Figure 5.2.1 Global Market Forecast for Nicotrol 2013-2023
Figure 5.3 Market Forecast for Habitrol/Nicotinell 2013-2023
Figure 5.4 Market Forecast for Nicorette 2013-2023
Figure 6.1 Global Chantix/ Champix Market 2008 – 2012
Figure 6.1.a Global Chantix/ Champix Market 2013 – 2023
Figure 6.1.b Geographic Breakdown for Chantix / Champix 2012 & 2023
Figure 6.2 Global Zyban Market 2013 – 2023
Figure 8.3.1.3 Geographic Breakdown
Figure 8.3.1.3.1 Market Share of e-cigarette Sales in the US Convenience Stores by Brand
Figure 8.3.1.4 Market Forecast for E-Cigarettes 2013-2023
COMPANIES
22nd Century Group, Inc
Acrux
Alcon Inc
Altria Group Inc
Alza Corporation
American Lung Association and Cancer Advocacy Coalition of Canada
Aradigm Corporation
Biota Holdings Ltd
Biota Pharmaceuticals, Inc.
Birlaveda
British American Tobacco
Celtic Pharmaceuticals
Cipla
CN Creative
Cytos Biotechnology
Elder Pharmaceuticals limited
EverSmoke Electronic Cigarettes
Evotec AG
Extab Corporation
Frii Inc
GlaxoSmithKline
Green Smoke Inc
Imperial Tobacco
Independent Pharmaceutica AB
Institute of Human Behaviour & Allied Sciences
Invion Limited
Johnson & Johnson
KLOX Technologies
Lorillard Inc
McNeil
Nabi Biopharmaceuticals
NAL Pharmaceuticals
National Institute on Drug Abuse
Nicobrand
Niconovum AB
NJOY
Novartis
Nu Mark LLC
Perrigo
Pfizer Inc
Pure Cigs, LLC
Reynolds American Inc
RML Hospital and Chronic Care Foundation
Sandoz Pharmaceuticals
Selecta Biosciences, Inc
Shanghai Johnson & Johnson Pharmaceutical Ltd
Sopharma
South Beach Smoke
Sun Pharma
Taranabant, Merck & Co
Teva Pharmaceuticals
U.S. Preventive Services Task Force
University of Chicago
Vapor King
Volcano Fine Electronic Cigarettes
Watson Pharmaceuticals
White Cloud Electronic Cigarettes
Figure 2.2.1: Prevalence of tobacco use among adults in selected countries—males and females, 2010
Figure 2.2.4.1 Global Market Size as per Skin Cancer Type – Incidences
Figure 2.2.2 Non-Smoking Adults Working Indoors Who Are Exposed to Second-hand Tobacco Smoke, 2008 – 2010
Figure 2.2.3 Adult Smokers Who Do Not Believe, or Do Not Know That Smoking Causes Specific Diseases, by Country
Chart 2.2.5: Average Retail Price and Taxation (Excise and Total) of Most Sold Brands of Cigarettes, 2010
Figure 3.1 Global Smoking Cessation Market Forecasts 2013 to 2023
Figure 3.1.1 Global NRT Smoking Cessation Market Forecast 2013-2023
Figure 3.1.1.a Global NRT Smoking Cessation Market Share by Product Type
Figure 3.1.2 Global Prescription Drugs Smoking Cessation Market Forecast 2013-2023
Figure 4.a Global Market Share for Selected Countries 2013
Figure 4.b Global Market Share for Selected Countries 2018
Figure 4.c Global Market Share for Selected Countries 2023
Figure4.1. The US Smoking Cessation Market Forecast 2012-2023 ($/m)
Figure 4.2 Retail Sales of NRT Products in the UK 2012
Figure 4.2.a. The UK Smoking Cessation Market Forecast 2012-2023 ($ Million)
Figure 4.3. The France Smoking Cessation Market Forecast 2012-2023 ($ Million)
Figure 4.4 The German Smoking Cessation Market Forecast 2012-2023 ($ Million)
Figure 4.5. The Spanish Smoking Cessation Market Forecast 2012-2023 ($ Million)
Figure 4.6 The Italian Smoking Cessation Market Forecast 2012-2023 ($/m)
Figure 4.7 The Japanese Smoking Cessation Market Forecast 2012-2023 ($ Million)
Figure 4.8 The ROW Smoking Cessation Market Forecast 2012-2023 ($ Million)
Figure 5.1 Market Forecast for Nicoderm CQ 2013-2023
Figure 5.1.a Geographic Breakdown for Nicoderm CQ 2012 & 2023
Figure 5.2 Global Revenue for Nicotrol 2010-2012
Figure 5.2.1 Global Market Forecast for Nicotrol 2013-2023
Figure 5.3 Market Forecast for Habitrol/Nicotinell 2013-2023
Figure 5.4 Market Forecast for Nicorette 2013-2023
Figure 6.1 Global Chantix/ Champix Market 2008 – 2012
Figure 6.1.a Global Chantix/ Champix Market 2013 – 2023
Figure 6.1.b Geographic Breakdown for Chantix / Champix 2012 & 2023
Figure 6.2 Global Zyban Market 2013 – 2023
Figure 8.3.1.3 Geographic Breakdown
Figure 8.3.1.3.1 Market Share of e-cigarette Sales in the US Convenience Stores by Brand
Figure 8.3.1.4 Market Forecast for E-Cigarettes 2013-2023
COMPANIES
22nd Century Group, Inc
Acrux
Alcon Inc
Altria Group Inc
Alza Corporation
American Lung Association and Cancer Advocacy Coalition of Canada
Aradigm Corporation
Biota Holdings Ltd
Biota Pharmaceuticals, Inc.
Birlaveda
British American Tobacco
Celtic Pharmaceuticals
Cipla
CN Creative
Cytos Biotechnology
Elder Pharmaceuticals limited
EverSmoke Electronic Cigarettes
Evotec AG
Extab Corporation
Frii Inc
GlaxoSmithKline
Green Smoke Inc
Imperial Tobacco
Independent Pharmaceutica AB
Institute of Human Behaviour & Allied Sciences
Invion Limited
Johnson & Johnson
KLOX Technologies
Lorillard Inc
McNeil
Nabi Biopharmaceuticals
NAL Pharmaceuticals
National Institute on Drug Abuse
Nicobrand
Niconovum AB
NJOY
Novartis
Nu Mark LLC
Perrigo
Pfizer Inc
Pure Cigs, LLC
Reynolds American Inc
RML Hospital and Chronic Care Foundation
Sandoz Pharmaceuticals
Selecta Biosciences, Inc
Shanghai Johnson & Johnson Pharmaceutical Ltd
Sopharma
South Beach Smoke
Sun Pharma
Taranabant, Merck & Co
Teva Pharmaceuticals
U.S. Preventive Services Task Force
University of Chicago
Vapor King
Volcano Fine Electronic Cigarettes
Watson Pharmaceuticals
White Cloud Electronic Cigarettes
